Singulex is an immunodiagnostics company at the forefront of Single Molecule Counting technology, a novel immunoassay technology recognized for unprecedented ultra-sensitivity in the precision measurement of biomarkers. Singulex is the developer of the Sgx Clarity System, a fully-automated, in vitro diagnostics platform powered by Single Molecule Counting technology. With up to 1,000 times more sensitivity than existing technologies, Single Molecule Counting reveals the presence or absence of disease more clearly and definitively than was possible before. Assays to detect and rule out cardiac, infectious, and inflammatory diseases are in development. Singulex is also developing a point of care platform and exploring applications beyond the clinical setting. For more information, please visit singulex.com or singulexclarity.eu